Chih‐hsiang Leng - Infectious Diseases

Author Information

Chih-hsiang Leng is a prominent researcher in the field of infectious diseases and vaccinology, currently affiliated with the National Institute of Infectious Diseases and Vaccinology at the National Health Research Institutes in Miaoli, Taiwan. Additionally, Leng is associated with the Graduate Institute of Immunology at China Medical University in Taichung, Taiwan. His work is primarily focused on understanding immune responses and developing therapeutic interventions, particularly in relation to infectious agents and vaccine delivery systems.

Research Contributions

Chih-hsiang Leng has made significant contributions to the understanding of immune mechanisms and vaccine development. His research has explored various aspects of infectious diseases, including the development of novel antigen delivery systems and therapeutic vaccines. Leng has investigated the role of pneumolysin from Streptococcus pneumoniae in inflammatory conditions and has developed innovative strategies for inducing antitumor immunity through targeted antigen delivery. His work also extends to evaluating the efficacy of vaccines and immunogenic compounds in activating immune responses across different species.

Aliases

Chih-hsiang Leng is also known by other names, including C. H. Leng and C. Leng. These aliases are often used in various publications and scientific contributions.

Publication and Citation Metrics

Metric	Value
Total Citation Count	1669
H-index	23
Total Paper Count	75

Publications:

Truncated Pneumolysin from Streptococcus pneumoniae as a TLR4-Antagonizing New Drug for Chronic Inflammatory Conditions

DOI: 10.3390/cells9051183

Year: 2020

Domain 4 of pneumolysin from Streptococcus pneumoniae is a multifunctional domain contributing TLR4 activating and hemolytic activity.

DOI: 10.1016/j.bbrc.2019.07.063

Year: 2019

Delivery of Antigen to CD8+ Dendritic Cells by Fusing Antigen With Formyl Peptide Receptor-Like 1 Inhibitor Protein Induces Antitumor Immunity

DOI: 10.3389/fimmu.2019.01839

Year: 2019

P1.04-04 Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity

DOI: 10.1016/J.JTHO.2018.08.719

Year: 2018

A therapeutic vaccine targeting HPV E6/E7 with intrinsic Toll-like receptor 2 agonist activity induces antitumor immunity.

DOI:

Year: 2018

Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity

DOI: 10.3389/fimmu.2018.00822

Year: 2018

Polysorbasome: A Colloidal Vesicle Contoured by Polymeric Bioresorbable Amphiphiles as an Immunogenic Depot for Vaccine Delivery.

DOI: 10.1021/acsami.8b03044

Year: 2018

A novel antigen delivery system via FcÎ³ receptors induces robust immune responses

DOI: 10.21767/2471-304X-C1-003

Year: 2018

CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses

DOI: 10.1038/s41598-017-17609-2

Year: 2017

Identification of Immunoreactive Peptides of Toxins to Simultaneously Assess the Neutralization Potency of Antivenoms against Neurotoxicity and Cytotoxicity of Naja atra Venom

DOI: 10.3390/toxins10010010

Year: 2017

How Can Transmission Be Prevented?

How are Chest CT Scans Performed?

What are the Symptoms of Salmonella Infection?

What are Immunodeficiency Disorders?

What are the Prevention Strategies?

How Are Respiratory Symptoms Diagnosed?

Can Condoms Be Used for All Types of Sexual Activities?

What Measures Can Be Taken to Prevent Transmission from Asymptomatic Carriers?

What Treatments are Available for Bacterial Infections?

How Do We Address the Challenge of Antimicrobial Resistance?

Partnered Content Networks

Relevant Topics